Journal of psychopharmacology (Oxford, England)
February 5, 2026
Benjamin R. Lewis, Matthew J Reid, Andrew M Novick et al.
Classical psychedelics-a broad class of compounds that include psilocybin, lysergic acid diethylamide, dimethyltryptamine, and mescaline-have shown significant promise for the treatment of mental health conditions in recent clinical trials. Organizations such as the National Network of Depression Centers (NNDCs) can play a pivotal role in uniting researchers and clinicians working in this field...
PLoS Medicine
September 19, 2025
Benjamin R. Lewis, John Hendrick, Kevin Byrne et al.
5 citations
Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress Reduction (MBSR) and psilocybin have been reported to reduce depressive symptoms, but the efficacy of the combination requires comparison to an active treatment control. We sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR...
medRxiv
2025
Benjamin R. Lewis, John Hendrick, Kevin Byrne et al.
3 citations
preprint
Abstract Objective This clinical trial sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR for frontline healthcare providers with symptoms of depression and burnout related to the COVID-19 pandemic. Methods This was a randomized controlled trial that enrolled physicians and nurses with frontline clinical work during the COVID-19 pandemic and symptoms of depression and...
Journal of Pain and Symptom Management
September 1, 2023
Benjamin R. Lewis, Eric L Garland, Kevin Byrne et al.
60 citations
Psilocybin-assisted psychotherapy shows promise in treating depression and existential distress in people with serious medical illness. However, its individual-based methodology poses challenges for scaling and resource availability. The HOPE trial (A Pilot Study of Psilocybin Enhanced Group Psychotherapy in Patients with Cancer) is an Institutional Review Boards-approved open-label feasibility...
Focus
July 1, 2023
Benjamin R. Lewis, Kevin Byrne
9 citations
Posttraumatic stress disorder (PTSD) is a common chronic and disabling psychiatric disorder that may develop after exposure to a traumatic life event. There are existing evidence-based psychotherapies and pharmacotherapies for PTSD; however, these treatments have significant limitations. 3,4-methylenedioxymethamphetamine (MDMA) was granted "breakthrough therapy" status by the U.S. Food and Drug...
Journal of Psychedelic Studies
June 19, 2023
Kevin Byrne, Spencer Lindsay, Nicholas Baker et al.
4 citations
Abstract Background and aims Most modern modalities of psychedelic-assisted psychotherapy (PAP) aim to minimize harm and maximize support by utilizing close, formalized supervision for a single participant per session. However, these substances are used naturalistically in a wide variety of settings. Our goal was to evaluate the perceived benefits and harms of naturalistic psychedelic use in...
Journal of Psychedelic Studies
January 18, 2023
Benjamin R. Lewis, Kevin Byrne, John Hendrick et al.
22 citations
Abstract Background Psilocybin-assisted psychotherapy has demonstrated significant promise as a treatment for depression, anxiety, and existential distress associated with serious medical illness and has generally been employed on an individual basis, which presents challenges for scaling and resource availability. There are also compelling theoretical reasons to suggest that group-based...
Journal of Psychedelic Studies
September 15, 2021
Benjamin R. Lewis, Kevin Byrne
1 citation
Abstract The recently published Imperial College study of a Phase II, double-blind, randomized, controlled trial comparing psilocybin-assisted therapy to a six-week titration of escitalopram for Major Depressive Disorder (MDD) should raise concerns for this illness category as a target of early psychedelic research given a goal of FDA approval. There are three reasons why MDD is the wrong...